SB-236057-A: A Selective 5-HT(1B) Receptor Inverse Agonist
by
Roberts C, Watson J, Price GW, Middlemiss DN.
Psychiatry Centre of Excellence for Drug Discovery,
GlaxoSmithKline, New Frontiers Science Park,
Third Ave., Harlow, Essex, CM19 5AW, UK.
Claire_Roberts-1@gsk.com
CNS Drug Rev 2001 Winter;7(4):433-444


ABSTRACT

5-HT(1B) autoreceptors are involved in the control of extracellular 5-HT levels from both the terminal and cell body regions of serotonergic neurons. In this manuscript we review the pharmacological and pharmacokinetic data available for the selective and potent 5-HT(1B) receptor inverse agonist, SB-236057-A (1'-ethyl-5-(2'-methyl-4'-(5-methyl-1,3,4-oxadiazolyl-2-yl)biphenyl-4-carbonyl)-2,3,6,7-tetrahydrospiro {furo[2,3-f]indole-3,4'-piperidine} hydrochloride). SB 236057-A has been shown to have high affinity for human 5-HT(1B) receptors (pK(i) = 8.2) and displays 80 or more fold selectivity for the human 5-HT(1B) receptor over other 5-HT receptors and a range of additional receptors, ion channels and enzymes. In functional studies at human 5-HT(1B) receptors SB-236057-A displayed inverse agonism (pA(2) = 8.9) using [(35)S]GTP[gamma]S binding, and silent antagonism (pA(2) = 9.2) using cAMP accumulation. SB-236057-A also acted as an antagonist at the 5-HT terminal autoreceptor as measured by [(3)H]5-HT release from electrically stimulated guinea pig and human cortical slices. In the guinea pig, pharmacokinetic analysis demonstrated that SB-236057-A was bioavailable and according to in vivo pharmacodynamic assays it enters brain and has a long duration of action. Importantly no side effect liability was evident at relevant doses from anxiogenic, cardiovascular, sedative or migraine viewpoints. In vivo microdialysis studies demonstrated that SB-236057-A is an antagonist in the guinea pig cortex but has no effect on extracellular 5-HT levels per se. In contrast, SB-236057-A increased extracellular 5-HT levels in the guinea pig dentate gyrus. This increase in 5-HT release was comparable to that observed after 14 days of paroxetine administration. SB-236057-A has been a useful tool in confirming that, in either guinea pigs or humans, the terminal 5-HT autoreceptor is of the 5-HT(1B) subtype. It appears that acute 5-HT(1B) receptor blockade, by virtue of increased 5-HT release in the dentate gyrus, may provide a rapidly acting antidepressant.
TCAs
SSRIs
5-HT1
5-HT2
5-HT3
5-HT1a
5-HT2c
Anpirtoline
Eltoprazine
Zolmitriptan
AR-A000002
Knockout mice
5-HT2c/5-HT2b
5-HT1a v 5-HT1b
SSRIs and 5-HT1b
MDMA and 5-HT1a
MDMA and 5-HT1b
5-HT1b and reward
5-HT1b and anxiety
5-HT1b and aggression
Aggression and serotonin
5-HT1b autoreceptors and SSRIs
5-HT1a agonists as antidepressants
5-HT-moduline, serotonin and mood
Extracellular serotonin and 5-HT1b blockade
5-HT1b and 5-HT1d agonists and antagonists


Refs
and further reading

HOME
HedWeb
Nootropics
erythroxylum-coca.com
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Good Drug Guide

The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family